Up to $20,000 available to the digital health company that solves one of the challenges proposed by MSD

MSD is looking for innovators to solve 7 health-related challenges aiming to support physician education or patient disease management. The 3 digital solutions with the most outstanding value will receive up to $20,000 each to be launched in a local market. MSD will also work side by side with the winning solvers to facilitate the roll-out of their solution.

As a leading pharmaceutical company, MSD is aware of the need to incorporate innovation to deliver the best possible value. However, the best ideas may not always pop up where challenges are identified. That is why MSD wants to support and partner with external talent to collaboratively develop competitive solutions following a win-win-win approach.

How it works

The Innovation Factory initiative aims to give support to the companies that come up with the best ideas to solve one of the 7 challenges identified in the EEMEA Region (Eastern Europe, Middle East and Africa) by local MSD teams.

The selection is done in four steps:

  • Solutions submitted before 31st October are reviewed by the challenge owners (the local MSD teams).
  • Each country will select the best solution for its proposed challenge.
  • During co-creation sessions the selected company and the local MSD team will work together in an improved proposal to be jointly presented in a Final event.
  • At the Final event in January 2018, the 7 finalists will pitch their solution in front of a senior jury from MSD. The jury will award 3 winners.

The prizes

Each of the 3 winners will receive the following:
  • Up to $20,000 to pilot their solution in the challenge-related local market.
  • Support from MSD local team to connect with the local ecosystem (eg. medical professional associations), deal with potential regulatory issues and disseminate leveraging MSD local channels. It will also contribute with expertise and business know-how.
  • If the local launch is a success after 12 months, its outcomes will be globally shared within MSD to investigate further implementation beyond the initial market.

All 7 finalists will get a 500€ grant to cover travel expenses to attend the Final event in Istanbul, and the opportunity to optimize their proposal in collaboration with the local MSD team that proposed the challenge. They will also receive visibility through the initiative communication channels.

The 7 challenges in a nutshell

The local teams have highlighted 7 needs of healthcare professionals or patients that could be solved with the support of digital technologies. A brief description of them follows:

Diabetes Guru - Egypt

Provide healthcare professionals dealing with diabetes with a (digital) solution that facilitates access to updated information on diabetes management and/or to perform related calculations.

GAP Pro - Gulf

Aid healthcare professionals to better prescribe antibiotics to their patients while fighting against Antimicrobial Resistance.

Managing Pain - Iraq

Help physicians to better support their patients with pain.

Diabetes Coach - Saudi Arabia

Assist Type-2 diabetic patients to better manage their disease, including their adherence to medication and lifestyle changes.

InfoVacc - South Africa

Launch a digital solution that helps parents to manage their children's vaccination calendar.

AnesTouch - Turkey

Support anaesthesiologists with their continuous education (e.g. at the operation room) or their team building with surgeons.

InnoBooth - Ukraine

Try innovative proposals for attracting visitors to the MSD booth and deliver them a memorable and informative experience at clinical conferences.

Submit your solution or solutions, in case you apply for more than one challenge. Applications will be reviewed and one finalist per challenge will be selected. Application ends 31 October.

For further information and to apply, please visit:
https://www.msdinnovationfactory.com

About the MSD Innovation Factory
Since 2016 the MSD Innovation Factory has been established as an open innovation vehicle for the EEMEA (Eastern Europe, Middle East and Africa) region with the main objective of finding co-creation opportunities with external partners to deliver sustainable solutions for our patients and customers.

MSD is a global healthcare company with a 125-year history of working to make a difference. MSD´s vision is to make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

The Innovation Factory is supported by TICBioMed, a business association specialized digital health.

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Probiotics can protect the skeletons of older wome…

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteri...

Alzheimer's breakthrough: Brain metals that may dr…

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegen...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

In mice, stem cells seem to work in fighting obesi…

Obesity is an increasing global health problem associated with several comorbidities and a high risk of mortality. A wide spectrum of interventions has been proposed for ...

FDA takes steps to foster greater efficiency in bi…

Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as w...

Research shows how a moderate dose of alcohol prot…

For at least 20 years, research has shown that for many people, moderate consumption of alcohol can protect the heart, but the reason for this is poorly understood. A stu...

'Kiss of death' cancer

It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negativ...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...